News

FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute ...
Medscape7h
Most Chronic Hepatitis B Diagnoses in US Are Late
A retrospective analysis of a privately insured US database found many chronic hepatitis B cases are diagnosed incidentally ...
MedPage Today19h
Mavyretz Approved for Acute Hepatitis C; ALD Deaths Double; Entyvio in Pregnancy
The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...
PharmExec22h
FDA Approves Expanded Indication for AbbVie’s Mavyret in Acute Hepatitis C
Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...